Lv1
90 积分 2024-10-09 加入
Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs
3个月前
已完结
Epidemiological impact of Polatuzumab vedotin plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) use in previously untreated Diffuse Large B-cell Lymphoma (DLBCL) on Second Line (2L) treatment: an ad hoc analysis from POLARIX study
3个月前
已关闭
Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study
3个月前
已关闭
Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
3个月前
已完结
Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
3个月前
已关闭
Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
3个月前
已关闭
皖公网安备34019202002308
